StockData
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. (SLS) stock

SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$14.86−3.09 (-17.21%)

Close on Nov 19, 2026Market cap $3.00BP/E –Yield –

SELLAS Life Sciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

SELLAS Life Sciences's free cash flow for the twelve months ending Dec 31, 2016 was -$11.86M. For fiscal 2016 it was -$11.86M. The highest annual figure on record is -$10.36M in fiscal 2010.

Annual free cash flow

PeriodPeriod endValueChange
FY2016Dec 31, 2016-$11.86M–
FY2015Dec 31, 2015-$48.31M–
FY2014Dec 31, 2014-$42.93M–
FY2013Dec 31, 2013-$29.25M–
FY2011Dec 31, 2011-$14.72M–
FY2010Dec 31, 2010-$10.36M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2016Dec 31, 2016$25.07M–
Q3 FY2016Sep 30, 2016-$12.21M–

More SELLAS Life Sciences figures

See a number that looks wrong?